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NOTES AND COMMENTS 
Rubella: Current Status of Immunization 
E. L . Quinn, M.D., Frank Cox, M.D. and Donald Romig, M.D.* 
The chief cause of concern with 
rubella—German measles—is its effect 
on the fetus when the virus infects a 
pregnant woman. An estimated 247,-
000 women in their first trimester of 
pregnancy contracted rubella in the 
1963-64 epidemic.^  The results: 8,000 
to 30,000 fetal deaths and approxi-
mately 20,000 children born with con-
genital anomalies which included deaf-
ness, eye defects, mental retardation 
and heart lesions. 
Since epidemics of rubella occur at 
6 to 7-year intervals, usually in spring, 
U.S. authorities are concerned about 
the repetition of this problem in 1970-
1971. Fortunately, the recent develop-
ment and availability of an effective 
rubella vaccine may avert this tragedy 
if immunization is properly and widely 
used. 
The vaccine is the direct descendant 
of viruses first isolated by Parkman, 
and independently by Weller and their 
co-workers in 1961. In the United 
States, it is expected that the vaccine 
will control rubella through the estab-
lishment of "herd immunity" among 
children, the group in which the disease 
is most common. It is the children who 
usually transmit the teratogenic virus to 
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the 15%to 20% of pregnant women 
who are susceptible. Because mass 
vaccination programs have largely 
eliminated polio and sharply curtailed 
measles (rubeola) by the establishment 
of herd immunity, it is felt the same 
can be accomplished with the rubella 
vaccine. To this end, the live, attenu-
ated rubella virus vaccine should be 
given to all children—boys as well as 
girls—between the ages of one year 
and extending through the elementary 
school population. 
In addition, the physician will be 
requested to give the vaccine to many 
adult women. The susceptibility to ru-
bella in these patients may be demon-
strated by absence of specific serum 
hemagglutinating antibody. Since the 
vaccine virus can infect the fetus, im-
munization should be used only if preg-
nancy can be excluded in sexually-
active women of child-bearing age and 
wiU be avoided for at least three months 
after vaccination. This requires a nega-
tive pregnancy test, administration of 
vaccine during a menstrual period or 
immediately after childbirth. Preven-
tion of conception must be assurred by 
abstinence or use of effective contra-
ceptives during the ensuing few months. 
In children, reactions to vaccine are 
rare, ie, occasional mild fever, local 
soreness at the site of injection and 
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arthralgia. Rash was reported in only 
a few instances. Spread of the vaccine 
virus to others has not been a problem. 
Arthralgia and transient arthritis oc-
cur more frequently in women than in 
children. Further attenuation of the 
virus in the vaccine may reduce ad-
verse reactions but may also reduce 
the vaccine's protective values. When 
they were adequately prewarned, pa-
tients to whom we gave the vaccine 
willingly accepted the possibility and 
occurrence of adverse reactions. 
The use of the live rubeUa virus 
vaccine should be avoided in patients 
with altered immune states or hyper-
sensitivity to vaccine components (in-
dicated on the label). Also, present 
recommendations are that administra-
tion should be separated by at least 
one month from the administration of 
other live virus vaccines. 
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